By studying the biochemical and functional properties of these BTK mutants in DLBCL cell lines, we made the unexpected finding that kinase-inactive BTK mutants were as efficient at transducing BCR signaling as their WT counterpart. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.